Udvalget for Humanmedicinske Lægemidler (CHMP) fandt, at fordelene ved Sprimeo opvejer risiciene ved behandling af essentiel hypertension.
The Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Sprimeo are greater than its risks for the treatment of essential hypertension.